ABS, HHI and KSOE Collaborate on Green Hydrogen Production and Carbon Capture and Storage
4.11.2021 12:00:00 EET | Business Wire | Press release
At COP26, ABS, Hyundai Heavy Industries (HHI) and Korea Shipbuilding and Offshore Engineering (KSOE) have announced two landmark joint development projects (JDPs) to develop decarbonization technologies to support global sustainability ambitions.
The JDPs address green hydrogen production and offshore carbon capture and storage (CCS), two technologies which will be critical to achieving net zero.
ABS, HHI and KSOE will jointly develop technical guidance for green hydrogen production from offshore platforms as a key first step to the design and construction of a facility by 2025. The guidance will facilitate the development of production facilities providing a vital contribution in the growth of a global green hydrogen economy.
The project will utilize the electrolysis of seawater to generate green hydrogen. Later stages potentially include ABS Approval in Principle (AIP) and generic design approval, supporting engineering development right through to project construction.
A second offshore carbon capture JDP is focused on securing an AIP for HHI and KSOE’s design for a CO2 injection platform for offshore storage. The platform is designed to be able to store 400,000 tons of captured and liquefied CO2 every year from 2025.
The announcement is timed to coincide with the 2021 United Nations Climate Change Conference, COP26, in Glasgow, where the potential of green hydrogen to support global sustainability ambitions and the capture, utilization and sequestration of carbon will be central to the discussion. Green hydrogen is a fuel created using entirely renewable energy sources. Currently, only one percent of hydrogen fuel is produced this way.
“We are pleased to leverage our expertise in the green hydrogen and CCS platform pathway for decarbonization offshore. These projects are part of our continuous endeavors and commitment to a sustainable future that is aligned with HHI Group’s ESG vision, “Beyond Blue Forward to Green”. We also promise that HHI Group will encourage new value creation to lead the market, satisfying customers’ desire for the achievement of GHG zero emissions,” said Won Ho JOO, HHI Senior Executive Vice President and Chief Technical Officer.
“It is a quite meaningful technological milestone in obtaining the JDPs for these innovative green hydrogen and CCS platforms in offshore. KSOE believes our self-developed model will contribute to the global decarbonization effort. Also, we are preparing the development of the whole value chains of both CO2 and green hydrogen. In the near future, we will show the Perfect Net Zero technology,” said Sung Joon KIM, CTO of KSOE.
“Securing the required quantities of zero-carbon fuels to power our industry’s transition will require significant scaling up of the global renewable energy sources. Green hydrogen will certainly have a critical role to play but we are starting from a very low base and increasing production is an urgent global priority. Meanwhile, carbon capture is a potential game changer, and ABS is working to accelerate development of both the technology and the vessels required to make it viable,” said ABS Chairman, President and CEO, Christopher J. Wiernicki. “We are proud to be able to use our industry-leading offshore and sustainability expertise to support advances in these key areas of technology and the international decarbonization drive.”
▬▬
About ABS
ABS, a leading global provider of classification and technical advisory services to the marine and offshore industries, is committed to setting standards for safety and excellence in design and construction. Focused on safe and practical application of advanced technologies and digital solutions, ABS works with industry and clients to develop accurate and cost-effective compliance, optimized performance and operational efficiency for marine and offshore assets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005089/en/
Contact information
For more information, contact:
ABS Media Relations
glewis@eagle.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release
LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
